EVOLUTION OF CANCER TREATMENT COST IN THE LAST 36 MONTHS: AN ANALYSIS FROM A HEALTH PAYER PERSPECTIVE IN BRAZIL

被引：0
|
作者：
Reis Neto, J. P. [1 ]
Busch, J. [2 ]
机构：
[1] CAPESESP, Rio De Janeiro, Brazil
[2] Souza Marques Univ, Rio De Janeiro, RJ, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD159
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 50 条
  • [41] Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer
    Eandi, Mario
    Gandini, Giorgio
    Povero, Massimiliano
    Zaniolo, Orietta
    Pradelli, Lorenzo
    Aprili, Giuseppe
    BLOOD TRANSFUSION, 2015, 13 (01) : 37 - 45
  • [42] Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
    Silverman, Stuart
    Agodoa, Irene
    Kruse, Morgan
    Parthan, Anju
    Orwoll, Eric
    JOURNAL OF OSTEOPOROSIS, 2015, 2015
  • [43] Staplers vs. loop-ligature: a cost analysis from the hospital payer perspective
    Richard Hilsden
    Nadia Khan
    Kelly Vogt
    Christopher M. Schlachta
    Surgical Endoscopy, 2019, 33 : 3419 - 3424
  • [44] SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIASIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
    Laires, P. A.
    Silva, C.
    Esparteiro, J.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [45] COST IMPLICATIONS OF RESTRICTING PALONOSETRON UTILIZATION FOR THE TREATMENT OF CINV: RESULTS FROM AN ANALYTIC MODEL FROM A PAYER PERSPECTIVE
    Powers, A.
    Sarnes, E.
    Knoth, R. L.
    Balu, S.
    Buchner, D.
    VALUE IN HEALTH, 2010, 13 (07) : A257 - A257
  • [46] COST-EFFECTIVENESS OF OCTREOTIDE LAR IN PATIENTS WITH METASTATIC NEUROENDOCRINE MIDGUT TUMORS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
    Takemoto, M. L.
    Fernandes, R. A.
    Chinen, R.
    Alves, M. R.
    VALUE IN HEALTH, 2010, 13 (07) : A265 - A265
  • [47] BUDGET IMPACT ANALYSIS OF ADOPTING THE VIDEO-ASSISTED THORACIC SURGERY FOR PATIENTS WITH LUNG CANCER FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
    Saggia, M.
    Follador, W.
    Valencia, J.
    VALUE IN HEALTH, 2016, 19 (03) : A300 - A301
  • [48] Environment and cancer in Brazil: an overview from a public health perspective
    Koifman, S
    Koifman, RJ
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2003, 544 (2-3) : 305 - 311
  • [49] COST EFFECTIVENESS OF ONABOTULINUMTOXINA VERSUS PTNS AND SNS FOR THE TREATMENT OF OVERACTIVE BLADDER FROM THE US PAYER PERSPECTIVE
    Hepp, Z.
    Yehoshua, A.
    Gultyaev, D.
    Lister, J.
    VALUE IN HEALTH, 2016, 19 (03) : A130 - A130
  • [50] Documenting the Benefits and Cost Savings of a Large Multistate Cancer Pathway Program From a Payer's Perspective
    Kreys, Eugene D.
    Koeller, Jim M.
    JOURNAL OF ONCOLOGY PRACTICE, 2013, 9 (05) : E241 - E247
12345